AstraZeneca has made a non-binding offer of about $10 billion for Rhythm Pharmaceuticals, Reuters reports. Rhythm’s latest results show the attraction of its rare-obesity franchise, but milestone payments complicate the headline price.
Third quarter net sales of $7.9 billion, an increase of 10.4% Third quarter net income of $318 million, a decrease of 1.2% Third quarter Adjusted EBITDA1 of $1.0 billion, an increase of
– Quarterly Revenue of $195.3 million – – Income from Operations of $29.0 million – – Net Income of $17.9 million – – Adjusted EBITDA1 of $39.8 million – – Backlog and
~ FDA granted priority review of BLA for ifezuntirgene inilparvovec (AMT-130) in Huntington’s disease; PDUFA target action date of May 1, 2027 ~ ~ Aligned with FDA on key elements of confirmatory study
— Multiple New Business Wins Continue to Strengthen Growing Pipeline — CHASKA, Minn., Nov. 04, 2026 (GLOBE NEWSWIRE) — Lifecore Biomedical, Inc. (NASDAQ: LFCR) (“Lifecore”), a fully integrated injectables contract development and
MALVERN, Pa., Nov. 04, 2026 (GLOBE NEWSWIRE) — Vishay Intertechnology, Inc., (NYSE: VSH), one of the world’s largest manufacturers of discrete semiconductors and passive electronic components, today announced results for the fiscal
Net income: $185.7 million for Q3 2026 $459.9 million for 9M 2026 Earnings per common unit: $6.42 for Q3 2026 $15.83 for 9M 2026 Net cash from operating activities: $235.4 million for
SPOKANE, Wash., Nov. 04, 2026 (GLOBE NEWSWIRE) — Avista Corp. (NYSE: AVA) today reported the following results for the third quarter of 2026 and the nine months ended Sept. 30, 2026 as
Achieved $60.1 million in RYTELO® (imetelstat) net product revenue in Q3 2026, an increase of 5% compared to Q2 2026 Reiterated 2026 RYTELO net product revenue at the mid-to-high end of the
HOUSTON, Nov. 04, 2026 (GLOBE NEWSWIRE) — Natural Resource Partners L.P. (NYSE:NRP) today reported third quarter 2026 results as follows: For the Three Months Ended Last Twelve Months Ended
Follow